Effect of Extra Virgin Olive Oil High in Bioactive Compounds on Atherosclerosis in Apoe‐Deficient Mice

Abstract

To test the effects of extra virgin olive oil (EVOO) enriched in specific bioactive compounds (EVOO HBC) on atherosclerosis and fatty liver, three isocaloric Western diets differing in the type of fat (palm, EVOO, or EVOO HBC) were fed to Apoe-deficient mice for 12 weeks. Plasma lipids, lipoprotein characterization, circulating CD36-expressing monocytes, and M2 peritoneal macrophages were quantified. Hepatic squalene and cross-sectional and en face atherosclerotic lesions were analyzed. Compared to the palm group, plasma triglyceride and glucose levels increased, while APOA1, paraoxonase 1 activity, and lipoprotein oxidation decreased in mice fed both EVOO groups. The latter stored liver squalene according to the amount consumed. En face and cross-sectional atherosclerotic lesions were lower in the EVOO groups. CD36 expression in circulating monocytes was lower and M2 peritoneal macrophages were higher in the EVOO groups. In males, there was a reduced presence of CD68-expressing cells in atherosclerotic plaques, while in females, there was a reduction in en face lesions that negatively correlated with high-density lipoprotein (HDL)-phospholipid efflux. The recruitment of macrophages into atherosclerotic plaques and the improvement of HDL efflux may be sex-dependent and attributable to the high content of squalene and a specific oleuropein aglycone.

Description

Keywords

Bibliographic citation

Martínez-Beamonte, R., Barranquero, C., Soler, L., Herrero-Continente, T., Rondón, A. C., Arnal, C., Estopañán, G., Lasheras, R., Rodriguez-Yoldi, M. J., Surra, J. C., Martín-Belloso, O., Odriozola-Serrano, I., Osada, J., & Navarro, M. Á. (2025). Effect of Extra Virgin Olive Oil High in Bioactive Compounds on Atherosclerosis in Apoe-Deficient Mice. Molecular Nutrition & Food Research, e70223. https://doi.org/10.1002/mnfr.70223
AGROVOC subjects
Ratón
Animal de laboratorio
Arteriosclerosis
Aceite de oliva
Lipoproteína
Dieta

Sponsorship

La presente investigación ha sido financiada por las subvenciones CIBEROBN (CB06/03/1012) CIBER Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III como iniciativa de FEDER-ISCIII, Ministerio de Ciencia e Innovación (PID2022-136414OB-I00), por el Ministerio de Ciencia e Innovación español con fondos de la Unión Europea NextGeneration EU, del Plan de Recuperación, Transformación y Resiliencia, número de subvención PRTR-C17, el contrato EU-PRIMA 2432 y el Programa Interreg SUDOE, número de subvención NEWPOWER, S1/1.1/E01116, en el marco del FEDER de la Unión Europea, que es un instrumento de financiación destinado a apoyar el desarrollo económico y social de las regiones europeas. También ha contado con el apoyo del Fondo Social Europeo-Gobierno de Aragón (B16_23R).